Why the study?
Does a small molecule cardiac myosin activator improve cardiac function in systolic heart failure?
Population
Systolic Heart Failure
Design
Preclinical
Authors
Loading...
Does not support clinical use of myosin activators; leaves open translation to systolic HF trials.
Does a small molecule cardiac myosin activator improve cardiac function in systolic heart failure?
Cardiac myosin activation via a small molecule represents a potential therapeutic approach to improve cardiac function in systolic heart failure.
Malik et al. (2011) studied this question.